BNTC
Benitec Biopharma Inc.
$13.44
+0.24 (+1.82%)
At close · Jul 7
Market Cap
$461.72M
Shares
34,354,334
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.44
Open$13.20
Day$12.80–13.69
52W$9.85–16.76
Avg vol 30d136K
Short int2.4M · 7.0% float · 28.9d
Short vol80%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+14%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
52%
mid-range
Momentum
relative strength
1-month return
+27%
trailing
6-month return
+11%
trailing
YTD return
0%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
1 of 87 funds reported for Jun 30 · net +1.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.00% of float · ▲ +3.1% MoM · 28.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
87 holders — near 3-yr high, broad support
Squeeze score
89
high risk · 0–100
Fundamentals
Revenue growth
−42%
Y/Y
EPS growth
+14%
Y/Y
Free cash flow
$-23.6M
Balance sheet
$97.7M
net cash
Quant / Vol
risk profile
Volatility
60%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
6.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 5 wks
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
52%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $12 › 200d $13 — 200d above 50d
Institutional flow
Accumulating
1 of 87 funds reported for Jun 30 · net +1.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.00% of float · ▲ +3.1% MoM · 28.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
87 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $10
Now $13 · 52%
52-wk high $17
vs 200-day avg +7%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BNTC
this stock
Benitec Biopharma Inc.
|
$461.72M | -0.2% | -42.2% | — | 7.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BNTC | +5.8% | +27.4% | +10.7% | +0.5% | -0.2% |
| SPY | +0.9% | +1.4% | +7.6% | +0.1% | +9.7% |
| vs SPY | +4.9% | +26.0% | +3.2% | +0.3% | -9.9% |